ABEONA THERAPEUTICS INC (ABEO) Stock Price, Forecast & Analysis
USA - NASDAQ:ABEO - US00289Y2063 - Common Stock
ABEO Key Statistics, Chart & Performance
The current stock price of ABEO is 4.2 USD. In the past month the price decreased by -21.64%. In the past year, price decreased by -34.37%.
ABEO Latest News, Press Relases and Analysis
ABEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About ABEO
Company Profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Company Info
ABEONA THERAPEUTICS INC
6555 Carnegie Ave, 4th Floor
CLEVELAND OHIO 75219 US
CEO: Michael Amoroso
Employees: 136
Phone: 16468134701
ABEONA THERAPEUTICS INC / ABEO FAQ
Can you describe the business of ABEONA THERAPEUTICS INC?
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The firm's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
What is the current price of ABEO stock?
The current stock price of ABEO is 4.2 USD. The price increased by 0.24% in the last trading session.
What is the dividend status of ABEONA THERAPEUTICS INC?
ABEO does not pay a dividend.
How is the ChartMill rating for ABEONA THERAPEUTICS INC?
ABEO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of ABEO stock?
ABEONA THERAPEUTICS INC (ABEO) has a market capitalization of 215.38M USD. This makes ABEO a Micro Cap stock.
Can you provide the ownership details for ABEO stock?
You can find the ownership structure of ABEONA THERAPEUTICS INC (ABEO) on the Ownership tab.
ABEO Technical Analysis
ABEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABEO. Both the profitability and financial health of ABEO have multiple concerns.
ABEO Financial Highlights
Over the last trailing twelve months ABEO reported a non-GAAP Earnings per Share(EPS) of -1.54. The EPS increased by 30.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14310.5% | ||
| ROA | 23.25% | ||
| ROE | 34.99% | ||
| Debt/Equity | 0.09 |
ABEO Forecast & Estimates
12 analysts have analysed ABEO and the average price target is 20.91 USD. This implies a price increase of 397.86% is expected in the next year compared to the current price of 4.2.
For the next year, analysts expect an EPS growth of 174.57% and a revenue growth 27374.5% for ABEO